We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Israeli drug titan Teva Pharmaceuticals and two other drugmakers have agreed to settlements in California in order to shake allegations of anticompetitive pay-for-delay deals. Read More
In a big week for Pfizer, the world’s second largest drugmaker earned the FDA’s approval for a biosimilar cancer treatment and signed up the agency’s former Commissioner Scott Gottlieb for its board. Read More
Eli Lilly’s lower-cost generic of its blockbuster insulin drug Humalog (insulin lispro) hit pharmacies on Wednesday following months of heat from both Congress and the White House over high insulin drug prices. Read More
The jury awarded Guo $1.8 million in damages, but it also found that she had violated company policy in her handling of the dispute and awarded Novartis damages. Read More
Novartis is hinting that it will appeal a New Jersey jury’s verdict awarding $1.5 million to a former executive who alleged that the company created a bogus drug study to disguise kickbacks to a leading drug distributor. Read More
The lawsuit claims Ranbaxy’s lawyers and Parexel, a consulting firm they retained, entered into an agreement “structured to shield Parexel’s audit work from any FDA scrutiny.” Read More
A group of indirect purchasers filed a RICO lawsuit against Indian drugmaker Ranbaxy, claiming the company cost them millions of dollars through a criminal enterprise. Read More
According to the complaint, the board pressed sales staff to specifically pressure doctors it identified as key opinion leaders to use their influence to increase prescribing. Read More